%0 Journal Article
%A Grafetstätter, Mirja
%A Hüsing, Anika
%A González Maldonado, Sandra
%A Sookthai, Disorn
%A Johnson, Theron S
%A Pletsch-Borba, Laura
%A Katzke, Verena
%A Hoffmeister, Michael
%A Bugert, Peter
%A Kaaks, Rudolf
%A Kuehn, Tilman
%T Plasma Fibrinogen and sP-Selectin are associated with the risk of lung cancer in a prospective study.
%J Cancer epidemiology, biomarkers & prevention
%V 28
%N 7
%@ 1538-7755
%C Philadelphia, Pa.
%I AACR
%M DKFZ-2019-01314
%P 1221-1227
%D 2019
%X While enhanced platelet activation and a procoagulant state may drive lung cancer progression and metastases, less is known about their role in earlier phases of cancer development. Thus, we evaluated whether pre-diagnostic biomarkers of platelet activation and coagulation are related to the risk of lung cancer in the prospective EPIC-Heidelberg Study using a case-cohort design.Levels of fibrinogen, soluble glycoprotein (sGP) IIb/IIIa, soluble P-selectin (sP-selectin), soluble thrombomodulin (sTM), and thrombopoietin (TPO) were measured in baseline plasma samples of a random subcohort (n=2,480) and incident cases of lung cancer (n=190). Multivariable-adjusted Cox proportional hazards regression analyses were used to obtain Hazard Ratios (HRs) of lung cancer across quartiles of biomarker levels.Fibrinogen (HR highest vs. lowest quartile: 1.91 [95 
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:31015200
%R 10.1158/1055-9965.EPI-18-1285
%U https://inrepo02.dkfz.de/record/143745